238 related articles for article (PubMed ID: 10919680)
1. From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs.
Kunka R; Andrews S; Pimazzoni M; Callejas S; Ziviani L; Squassante L; Daley-Yates PT
Respir Med; 2000 Jun; 94 Suppl B():S10-6. PubMed ID: 10919680
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group.
Tonnel AB; Bons J; Legendre M; Prud'Homme A; Bugnas B; Evano-Celli I; Stuart AM
Respir Med; 2000 Jun; 94 Suppl B():S29-34. PubMed ID: 10919683
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical transition to non-CFC pressurized metered dose inhalers.
Cripps A; Riebe M; Schulze M; Woodhouse R
Respir Med; 2000 Jun; 94 Suppl B():S3-9. PubMed ID: 10919679
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group.
Ayres JG; Millar AB; Sykes AP
Respir Med; 2000 Jun; 94 Suppl B():S42-50. PubMed ID: 10919685
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International study group.
Perruchoud AP; Lundback B; Yigla M; Sykes AP
Respir Med; 2000 Jun; 94 Suppl B():S35-41. PubMed ID: 10919684
[TBL] [Abstract][Full Text] [Related]
6. Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant.
Mackie AE; McDowall JE; Ventresca P; Bye A; Falcoz C; Daley-Yates PT
Clin Pharmacokinet; 2000; 39 Suppl 1():17-22. PubMed ID: 11140429
[TBL] [Abstract][Full Text] [Related]
7. Systemic exposure and urinary cortisol effects of fluticasone propionate formulated with hydrofluoroalkane in 4- to 11-year-olds with asthma.
Kim KT; Milgrom H; Yoon YK; Levy AL; Matz P; Welch MJ; Cahn A; Collins DA; Kathman S; Mehta R; Su SF; Kunka RL
J Clin Pharmacol; 2008 Jan; 48(1):108-16. PubMed ID: 18094223
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[TBL] [Abstract][Full Text] [Related]
9. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone : a cross-over study in healthy volunteers.
Leach CL; Davidson PJ; Hasselquist BE; Boudreau RJ
Chest; 2002 Aug; 122(2):510-6. PubMed ID: 12171824
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients.
Langley SJ; Sykes AP; Batty EP; Masterson CM; Woodcock A
Ann Allergy Asthma Immunol; 2002 May; 88(5):488-93. PubMed ID: 12027070
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate.
Fowler SJ; Orr LC; Sims EJ; Wilson AM; Currie GP; McFarlane L; Lipworth BJ
Chest; 2002 Aug; 122(2):618-23. PubMed ID: 12171841
[TBL] [Abstract][Full Text] [Related]
12. Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids.
Lumry WR; Conway MM; LaForce CF; Pearlman DS; Scott CA; Herje NE; Wu WW; Crim C
Ann Allergy Asthma Immunol; 2006 Jan; 96(1):51-9. PubMed ID: 16440533
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects.
Kempsford R; Handel M; Mehta R; De Silva M; Daley-Yates P
Respir Med; 2005 Apr; 99 Suppl A():S11-9. PubMed ID: 15777604
[TBL] [Abstract][Full Text] [Related]
14. Equivalence of salbutamol 200 microg four times daily propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. Eastern European study group.
Salat D; Popov D; Sykes AP
Respir Med; 2000 Jun; 94 Suppl B():S22-8. PubMed ID: 10919682
[TBL] [Abstract][Full Text] [Related]
15. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients.
Leach CL; Kuehl PJ; Chand R; Ketai L; Norenberg JP; McDonald JD
Ann Allergy Asthma Immunol; 2012 Mar; 108(3):195-200. PubMed ID: 22374204
[TBL] [Abstract][Full Text] [Related]
16. Re: Dose proportionality of fluticosone proportionate hydrofluoroalkane pressurized metered dose inhalers (pMDIS) and comparability with chlorofluorocarbon pMDIS.
Lipworth BJ
Respir Med; 2001 Feb; 95(2):160-3. PubMed ID: 11217914
[No Abstract] [Full Text] [Related]
17. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol.
Fireman P; Prenner BM; Vincken W; Demedts M; Mol SJ; Cohen RM
Ann Allergy Asthma Immunol; 2001 May; 86(5):557-65. PubMed ID: 11379808
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
[TBL] [Abstract][Full Text] [Related]
19. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants.
Richards J; Hirst P; Pitcairn G; Mahashabde S; Abramowitz W; Nolting A; Newman SP
J Aerosol Med; 2001; 14(2):197-208. PubMed ID: 11681651
[TBL] [Abstract][Full Text] [Related]
20. Fluticasone propionate via the Diskhaler or hydrofluoroalkane-134a metered-dose inhaler on methacholine-induced airway hyperresponsiveness.
Langley SJ; Holden J; Derham A; Hedgeland P; Sharma RK; Woodcock A
Chest; 2002 Sep; 122(3):806-11. PubMed ID: 12226017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
